Genmab and Biontech to advance lung cancer drug acasunlimab to Phase III
Genmab and Biontech presented data from a Phase II study of acasunlimab in lung cancer at ASCO in Chicago.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.